What's New
News
AFTD and Passage Bio Discuss Therapeutics Designed for FTD-GRN
AFTD recently spoke with Passage Bio Chief Executive Officer William Chou, M.D., about his colleagues’ work to…
AFTD and Denali Therapeutics Discuss Takeda Pharmaceuticals Partnership to Develop FTD-Focused Therapeutic
Recently, members of the Denali Therapeutics team provided insights into their work and partnership with Takeda to…
One-Night Performance of Acclaimed Play UnRavelled Examines Art, Science, and Dementia
AFTD staff and Board members attended a performance of the play UnRavelled at the San Francisco Conservatory…
AFTD and AviadoBio Discuss Therapeutic Treatment Protocols for FTD
AFTD recently spoke with AviadoBio Chief Executive Officer Lisa Deschamps about her colleagues’ work to develop a…
Groundbreaking Drug That Slows Progression of Alzheimer’s Receives Full FDA Approval
The U.S. Food and Drug Administration (FDA) has, for the first time, fully approved a drug that…
Dr. Chiadi Onyike Named AFTD Medical Advisory Council Chair-Elect
During their annual meeting at the 2023 Education Conference, AFTD’s Board of Directors named Chiadi Onyike, MD,…
